Roy Freeman1, Jennifer S Gewandter2, Catharina G Faber2, Christopher Gibbons2, Simon Haroutounian2, Giuseppe Lauria2, Todd Levine2, Rayaz A Malik2, J Robinson Singleton2, A Gordon Smith2, Josh Bell2, Robert H Dworkin2, Eva Feldman2, David N Herrmann2, Ahmet Hoke2, Noah Kolb2, Heikki Mansikka2, Anne Louise Oaklander2, Amanda Peltier2, Michael Polydefkis2, Elissa Ritt2, James W Russell2, Stephen Sainati2, Deborah Steiner2, Roi Treister2, Nurcan Üçeyler2. 1. From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico "Carlo Besta," Milan, Italy; Department of Biomedical and Clinical Sciences "Luigi Sacco" (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany. rfreeman@bidmc.harvard.edu. 2. From the Beth Israel Deaconess Medical Center (R.F., C.G.), Harvard Medical School, MA; University of Rochester Medical Center (J.S.G., R.H.D., D.N.H.), Rochester, NY; Department of Neurology (C.G.F.), School of Mental Health and Neuroscience, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Anesthesiology (S.H.), Washington University in St. Louis School of Medicine, St. Louis, MO; Neuroalgology Unit (G.L.), Fondazione IRCCS Istituto Neurologico "Carlo Besta," Milan, Italy; Department of Biomedical and Clinical Sciences "Luigi Sacco" (G.L.), University of Milan,Milan, Italy; Phoenix Neurological Associates (T.L.), Phoenix, AZ; Weill Cornell Medicine-Qatar (R.A.M.), Qatar Foundation, Education City, Doha, Qatar; University of Utah (J.R.S.), Salt Lake City, UT; Virginia Commonwealth University (A.G.S.), Richmond, VA; Biogen (J.B.), Cambridge, MA; University of Michigan (E.F.), Ann Arbor, MI; Johns Hopkins School of Medicine (A.H., M.P.), Baltimore, MD; University of Vermont (N.K.), Burlington, VT; Chromocell Corp (H.M.), North Brunswick, NJ; Harvard Medical School (A.L.O.), Boston, MA; Departments of Neurology and Medicine (A.P.), and Vanderbilt Heart and Vascular Institute, Nashville, TN; NuFactor Specialty Pharmacy (E.R.), Temecula, CA; University of Maryland (J.W.R.), Baltimore, MD; Aptinyx (S.S.), INC., Evanston. IL; Amgen (D.S.), Cambridge, MA; University of Haifa (R.T.), Haifa, Israel; and University of Würzburg (N.Ü.), Würzburg, Germany.
Abstract
OBJECTIVE: To present standardized diagnostic criteria for idiopathic distal sensory polyneuropathy (iDSP) and its subtypes: idiopathic mixed fiber sensory neuropathy (iMFN), idiopathic small fiber sensory neuropathy (iSFN), and idiopathic large fiber sensory neuropathy (iLFN) for use in research. METHODS: The Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities and Networks (ACTTION) public-private partnership with the Food and Drug Administration convened a meeting to develop consensus diagnostic criteria for iMFN, iSFN, and iLFN. After background presentations, a collaborative, iterative approach was used to develop expert consensus for new criteria. RESULTS: An iDSP diagnosis requires at least 1 small fiber (SF) or large fiber (LF) symptom, at least 1 SF or LF sign, abnormalities in sensory nerve conduction studies (NCS) or distal intraepidermal nerve fiber density (IENFD), and exclusion of known etiologies. An iMFN diagnosis requires that at least 1 of the above clinical features is SF and 1 clinical feature is LF with abnormalities in sensory NCS or IENFD. Diagnostic criteria for iSFN require at least 1 SF symptom and at least 1 SF sign with abnormal IENFD, normal sensory NCS, and the absence of LF symptoms and signs. Diagnostic criteria for iLFN require at least 1 LF symptom and at least 1 LF sign with normal IENFD, abnormal sensory NCS, and absence of SF symptoms and signs. CONCLUSION: Adoption of these standardized diagnostic criteria will advance research and clinical trials and spur development of novel therapies for iDSPs.
OBJECTIVE: To present standardized diagnostic criteria for idiopathic distal sensory polyneuropathy (iDSP) and its subtypes: idiopathic mixed fiber sensory neuropathy (iMFN), idiopathic small fiber sensory neuropathy (iSFN), and idiopathic large fiber sensory neuropathy (iLFN) for use in research. METHODS: The Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities and Networks (ACTTION) public-private partnership with the Food and Drug Administration convened a meeting to develop consensus diagnostic criteria for iMFN, iSFN, and iLFN. After background presentations, a collaborative, iterative approach was used to develop expert consensus for new criteria. RESULTS: An iDSP diagnosis requires at least 1 small fiber (SF) or large fiber (LF) symptom, at least 1 SF or LF sign, abnormalities in sensory nerve conduction studies (NCS) or distal intraepidermal nerve fiber density (IENFD), and exclusion of known etiologies. An iMFN diagnosis requires that at least 1 of the above clinical features is SF and 1 clinical feature is LF with abnormalities in sensory NCS or IENFD. Diagnostic criteria for iSFN require at least 1 SF symptom and at least 1 SF sign with abnormal IENFD, normal sensory NCS, and the absence of LF symptoms and signs. Diagnostic criteria for iLFN require at least 1 LF symptom and at least 1 LF sign with normal IENFD, abnormal sensory NCS, and absence of SF symptoms and signs. CONCLUSION: Adoption of these standardized diagnostic criteria will advance research and clinical trials and spur development of novel therapies for iDSPs.
Authors: G Lauria; D R Cornblath; O Johansson; J C McArthur; S I Mellgren; M Nolano; N Rosenberg; C Sommer Journal: Eur J Neurol Date: 2005-10 Impact factor: 6.089
Authors: Alexandra E Koulouris; Robert R Edwards; Kathleen Dorado; Kristin L Schreiber; Asimina Lazaridou; Sharika Rajan; Jeffrey White; Jenniffer Garcia; Christopher Gibbons; Roy Freeman Journal: Pain Med Date: 2020-10-01 Impact factor: 3.750
Authors: Jennifer S Gewandter; Christopher H Gibbons; Marta Campagnolo; Joonho Lee; Jenna Chaudari; Nam Ward; Laurie Burke; Guido Cavaletti; David N Herrmann; Justin C McArthur; James W Russell; A Gordon Smith; Shannon M Smith; Dennis C Turk; Robert H Dworkin; Roy Freeman Journal: Neurology Date: 2019-07-18 Impact factor: 9.910
Authors: N Strand; C Wie; J Peck; M Maita; N Singh; J Dumbroff; V Tieppo Francio; M Murphy; K Chang; D M Dickerson; J Maloney Journal: Curr Pain Headache Rep Date: 2022-04-06
Authors: Stephen A Johnson; Kamal Shouman; Shahar Shelly; Paola Sandroni; Sarah E Berini; P James B Dyck; Ernest Matthew Hoffman; Jay Mandrekar; Zhiyv Niu; Christopher J Lamb; Phillip A Low; Wolfgang Singer; Michelle L Mauermann; John Mills; Divyanshu Dubey; Nathan P Staff; Christopher J Klein Journal: Neurology Date: 2021-10-27 Impact factor: 9.910
Authors: Phillip Joseph; Carlo Arevalo; Rudolf K F Oliveira; Mariana Faria-Urbina; Donna Felsenstein; Anne Louise Oaklander; David M Systrom Journal: Chest Date: 2021-02-10 Impact factor: 10.262
Authors: Mariia V Lukashenko; Natalia Y Gavrilova; Anna V Bregovskaya; Lidiia A Soprun; Leonid P Churilov; Ioannis N Petropoulos; Rayaz A Malik; Yehuda Shoenfeld Journal: Pathophysiology Date: 2021-12-26
Authors: Ioannis N Petropoulos; Gulfidan Bitirgen; Maryam Ferdousi; Alise Kalteniece; Shazli Azmi; Luca D'Onofrio; Sze Hway Lim; Georgios Ponirakis; Adnan Khan; Hoda Gad; Ibrahim Mohammed; Yacob E Mohammadi; Ayesha Malik; David Gosal; Christopher Kobylecki; Monty Silverdale; Handrean Soran; Uazman Alam; Rayaz A Malik Journal: Front Pain Res (Lausanne) Date: 2021-08-19
Authors: Maurice Sopacua; Carla M L Gorissen-Brouwers; Bianca T A de Greef; Isis B T Joosten; Catharina G Faber; Ingemar S J Merkies; Janneke G J Hoeijmakers Journal: Clin Neurophysiol Pract Date: 2022-03-28